Please use this identifier to cite or link to this item:
Title: Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.
Austin Authors: Nicholaou, Theo;Ebert, Lisa;Davis, Ian D;Robson, Neil;Klein, Oliver ;Maraskovsky, Eugene;Chen, Weisan;Cebon, Jonathan S 
Affiliation: Ludwig Institute for Cancer Research, Cancer Vaccine Programme, Austin Hospital, Victoria, Australia
Issue Date: 1-Jun-2006
Publication information: Immunology and Cell Biology; 84(3): 303-17
Abstract: Since the early 1990s, numerous cancer Ag have been defined and for a handful of these there is now some clinical experience, which has made it possible to assess their value as targets for cancer immunotherapy. The cancer-testis Ag have been particularly attractive because their expression is limited to cancer and virtually no non-malignant cells apart from germ cells and trophoblast. Among these, NY-ESO-1 has been the focus of our attention. The exceptional immunogenicity of this Ag coupled with its widespread distribution among many cancer types make it a very good vaccine candidate, with the potential to be used in vaccines against many types of malignancies. This article reviews emerging knowledge about the biology of NY-ESO-1 and experience with the early clinical development of vaccines directed against NY-ESO-1. These early studies have yielded a wealth of information about the immunology of NY-ESO-1 and set the scene for future clinical strategies for immune targeting of cancer.
Gov't Doc #: 16681828
DOI: 10.1111/j.1440-1711.2006.01446.x
Journal: Immunology and cell biology
Type: Journal Article
Subjects: Antigens, Neoplasm.immunology
Cancer Vaccines.immunology
Lymphocytes, Tumor-Infiltrating.immunology
Membrane Proteins.immunology
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.